Curative effect of Insulin Ditel combined with Lialuru Peptide on type 2 diabetes in elderly patients with Metformin - resistant
ZHANG Jidong1 RONG Chao1 HU Juan2 SUN Xuju3
1.Department of Pharmacy, Huazhong University of Science and Technology Hospital, Hubei Province, Wuhan 430074, China;
2.Department of Surgical, Huazhong University of Science and Technology Hospital, Hubei Province, Wuhan 430074, China;
3.Department of Pharmacy, Liyuan Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Hubei Province, Wuhan 430074, China
Abstract:Objective To investigate the effect of Insulin Ditel combined with Lialuru Peptide on Metformin - resistant elderly patients with type 2 diabetes mellitus (T2DM). Methods From October 2017 to April 2019, the clinical data of 127 elderly patients with T2DM who failed to respond to Metformin treated in Huazhong University of Science and Technology Hospital were retrospectively analyzed. According to the treatment methods, the patients were divided into group A (40 cases treated with Insulin Ditel), group B (41 cases treated with Lialuru Peptide) and group C (46 cases treated with Insulin Ditel combined with Lialuru Peptide). The changes of body mass index (BMI), fasting plasma glucose (FPG), 2 h postprandial blood glucose (2hPBG), glycosylated hemoglobin (HbA1c), insulin resistance index (HOMA-IR) among the three groups were compared before and after treatment and the adverse reactions were compared among three groups. Results There were no significant differences in BMI, FPG, 2hPBG, HbA1c and HOMA-IR among the three groups before treatment (P > 0.05). After treatment, BMI, FPG, 2hPBG, HbA1c and HOMA-IR in the three groups were lower than those before treatment, and BMI, FPG, 2hPBG, HbA1c and HOMA-IR in group C were lower than those in group A and group B after treatment, with statistically significant differences (all P < 0.05). There was no significant difference in the incidence of adverse reactions among the three groups (P > 0.05). Conclusion In the elderly T2DM patients with Metformin-resistant, the combination of Insulin Ditel and Lialuru Peptide can significantly reduce BMI and improve the index of glucose metabolism, the effect is better than that of using alone, and it is safe.
张继东1 荣朝1 胡娟2 孙绪举3. 地特胰岛素联合利拉鲁肽对二甲双胍无效的老年2型糖尿病的疗效[J]. 中国医药导报, 2020, 17(21): 74-77.
ZHANG Jidong1 RONG Chao1 HU Juan2 SUN Xuju3. Curative effect of Insulin Ditel combined with Lialuru Peptide on type 2 diabetes in elderly patients with Metformin - resistant. 中国医药导报, 2020, 17(21): 74-77.
[1] 谷伟军,陆菊明,纪立农,等.2013年全国2型糖尿病患者治疗状况调查[J].中国糖尿病杂志,2015,7(4):213-217.
[2] Sanchez RE,Inzucchi SE. Metformin clinical use in type 2 diabetes [J]. Diabetologia,2017,60(9):1586-1593.
[3] Lefaucheur JP. Evaluation of the Efficacy of Insulin Combined with Metformin Tablets in the Treatment of Type 2 Diabetes Mellitus [J]. Diabetes New World,2015,33(1):23-29.
[4] 郭雯,李芳,陈频,等.单用二甲双胍控制不佳的2型糖尿病患者分别联用利拉鲁肽与甘精胰岛素26周的疗效及安全性比较[J].中华内分泌代谢杂志,2014,30(12):1086-1091.
[5] 贾真,何旺,张渭涛,等.利拉鲁肽联合二甲双胍在2型糖尿病患者中的防治效果及对机体免疫的影响研究[J].陕西医学杂志,2018,47(1):114-116.
[6] Mahabaleshwarkar R,Templin M,Gohs F,et al. Impact of Timely Treatment Intensification on Glycemic Goal Achievement in Patients With Type 2 Diabetes Failing Metformin Monotherapy [J]. Diabetes Educ,2017,43(5):495-505.
[7] 陈瑞阳.2014—2018年孝感市中心医院胰岛素类药物的使用情况分析[J].现代药物与临床,2019,34(3):843-847.
[8] 贾伟平,陆菊明.中国2型糖尿病防治指南(2017年版)编写说明[J].中华糖尿病杂志,2018,10(1):2-3.
[9] Florez JC. Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes:Where are the insulin resistance genes [J]. Diabetologia,2008,51(7):1100-1110.
[10] 杨毓莹,刘建民.探索维生素D及其活性类似物防治2型糖尿病的新途径[J].中华内分泌代谢杂志,2018,34(12):992-996.
[11] Booker C. The accelerator hypothesis:insulin resistance as the central cause of type 1 and type 2 diabetes [J]. Int J Obes,2010,34(1):210-211.
[12] 王永海,江梅菊,王琳,等.阿托伐他汀联合二甲双胍治疗老年2型糖尿病伴血脂异常的效果[J].中国医药导报,2018,15(12):113-116,155.
[13] 孙晓方,王越,赵文娟,等.利拉鲁肽对肥胖2型糖尿病患者胰高血糖素分泌功能的影响[J].中华内科杂志,2019, 58(1):33-38.
[14] 郭伟,李伟,侯小莉,等.利拉鲁肽对2型糖尿病轻度认知功能障碍患者炎性因子及认知功能的影响[J].中国医院药学杂志,2019,39(11):1179-1182.
[15] 倪卫惠,李骏,岳枝.利拉鲁肽对二甲双胍控制不佳的2型糖尿病非酒精性脂肪肝的疗效观察[J].药物生物技术,2017,24(6):528-530.
[16] 陆玉莲,钱铁镛,陈一丁,等.口服降糖药分别联合不同胰岛素类似物治疗血糖控制不佳2型糖尿病的临床研究[J].中国全科医学,2018,21(23):2785-2789.
[17] 张敏,叶海燕,陈景言,等.维格列汀联合二甲双胍治疗2型糖尿病的疗效和安全性[J].中国临床研究,2018, 31(6):763-766.
[18] 贺延娇,王蕊,郭斌.口服降糖药联合不同胰岛素类似物治疗血糖控制不佳2型糖尿病的临床研究[J].热带医学杂志,2019,19(4):472-476.
[19] 吴永和,游育东,杨晓霞,等.利拉鲁肽、吡格列酮对2型糖尿病并非酒精性脂肪肝的疗效[J].中外医学研究,2018,16(34):137-138.
[20] 李小景,荣秀花,欧宇苹,等.利拉鲁肽与胰岛素泵治疗超重2型糖尿病的疗效与安全性[J].中国医学创新,2019, 16(27):35-38.
[21] 徐鑫.地特胰岛素联合二甲双胍对老年新发2型糖尿病的治疗效果分析[J].河北医学,2018,14(10):27-32.
[22] 王存解,冯迎儿.地特胰岛素联合瑞格列奈治疗2型糖尿病的临床疗效观察[J].中国基层医药,2018,25(24):3155.
[23] 王新英.地特胰岛素治疗妊娠期糖尿病的疗效及对母婴结局的影响研究[J].中国现代医生,2019,57(4):60-62.
[24] 黄昆源.地特胰岛素联合格列美脲治疗初诊2型糖尿病的疗效分析[J].中国医药科学,2018,171(3):96-98.
[25] 廖平.地特胰岛素联合瑞格列奈治疗2型糖尿病患者的临床效果及其对血糖指标及低血糖发生的影响[J].中外医学研究,2018,16(23):9-11.
[26] 高轩.地特胰岛素联合格列美脲及阿卡波糖对继发性磺脲类药物失效的2型糖尿病的疗效观察[J].中国临床医生杂志,2019,47(7):818-820.